메뉴 건너뛰기




Volumn 112, Issue 3, 2013, Pages 427-435

Erratum: Early response evaluation for recurrent high grade gliomas treated with bevacizumab: A volumetric analysis using diffusion-weighted imaging (J Neurooncol, 10.1007/s11060-013-1072-z);Early response evaluation for recurrent high grade gliomas treated with bevacizumab: A volumetric analysis using diffusion-weighted imaging

Author keywords

Astrocytoma; Bevacizumab; Diffusion weighted imaging; Glioblastoma; Prognosis

Indexed keywords


EID: 84885038432     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1105-7     Document Type: Erratum
Times cited : (21)

References (27)
  • 2
    • 55849130720 scopus 로고    scopus 로고
    • Novel anti-angiogenic therapies for malignant gliomas
    • 19007739 10.1016/S1474-4422(08)70260-6 1:CAS:528:DC%2BD1cXhsFCrsLvO
    • Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152-1160
    • (2008) Lancet Neurol , vol.7 , pp. 1152-1160
    • Norden, A.D.1    Drappatz, J.2    Wen, P.Y.3
  • 4
    • 79958031331 scopus 로고    scopus 로고
    • Bevacizumab for the treatment of recurrent glioblastoma
    • 21603247 10.4137/CMO.S7232 1:CAS:528:DC%2BC3MXmsV2htro%3D
    • Chamberlain MC (2011) Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 5:117-129
    • (2011) Clin Med Insights Oncol , vol.5 , pp. 117-129
    • Chamberlain, M.C.1
  • 5
    • 55349088954 scopus 로고    scopus 로고
    • Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
    • 18836331 10.1097/PPO.0b013e3181867bd6
    • de Groot JF, Yung WK (2008) Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14:279-285
    • (2008) Cancer J , vol.14 , pp. 279-285
    • De Groot, J.F.1    Yung, W.K.2
  • 10
    • 0025281789 scopus 로고
    • Response criteria for phase II studies of supratentorial malignant glioma
    • 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D
    • Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
    • (1990) J Clin Oncol , vol.8 , pp. 1277-1280
    • Macdonald, D.R.1    Cascino, T.L.2    Schold, Jr.S.C.3    Cairncross, J.G.4
  • 13
    • 79961132632 scopus 로고    scopus 로고
    • Advances in MRI assessment of gliomas and response to anti-VEGF therapy
    • 21234719 10.1007/s11910-011-0179-x 1:CAS:528:DC%2BC3MXkvVSnsbs%3D
    • Pope WB, Young JR, Ellingson BM (2011) Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 11:336-344
    • (2011) Curr Neurol Neurosci Rep , vol.11 , pp. 336-344
    • Pope, W.B.1    Young, J.R.2    Ellingson, B.M.3
  • 14
    • 33750684658 scopus 로고    scopus 로고
    • Diffusion-weighted magnetic resonance imaging and its application to cancer
    • 17015238 10.1102/1470-7330.2006.0021
    • Charles-Edwards EM, de Souza NM (2006) Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer imaging 6:135-143
    • (2006) Cancer Imaging , vol.6 , pp. 135-143
    • Charles-Edwards, E.M.1    De Souza, N.M.2
  • 16
    • 77954113465 scopus 로고    scopus 로고
    • Predicting and monitoring cancer treatment response with diffusion-weighted MRI
    • 20575076 10.1002/jmri.22167
    • Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32:2-16
    • (2010) J Magn Reson Imaging , vol.32 , pp. 2-16
    • Thoeny, H.C.1    Ross, B.D.2
  • 17
    • 79952194217 scopus 로고    scopus 로고
    • Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas
    • 20798977 10.1007/s11060-010-0293-7
    • Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM (2011) Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. J Neurooncol 102:95-103
    • (2011) J Neurooncol , vol.102 , pp. 95-103
    • Ellingson, B.M.1    Malkin, M.G.2    Rand, S.D.3    Laviolette, P.S.4    Connelly, J.M.5    Mueller, W.M.6    Schmainda, K.M.7
  • 18
    • 75049085441 scopus 로고    scopus 로고
    • Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker
    • 19859666 10.1007/s11060-009-9981-6 1:CAS:528:DC%2BC3cXpsVaqtA%3D%3D
    • Jain R, Scarpace LM, Ellika S, Torcuator R, Schultz LR, Hearshen D, Mikkelsen T (2010) Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 96:423-431
    • (2010) J Neurooncol , vol.96 , pp. 423-431
    • Jain, R.1    Scarpace, L.M.2    Ellika, S.3    Torcuator, R.4    Schultz, L.R.5    Hearshen, D.6    Mikkelsen, T.7
  • 19
    • 84867799455 scopus 로고    scopus 로고
    • Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls
    • 22538078 10.3174/ajnr.A3053 1:STN:280:DC%2BC38rosVGktw%3D%3D
    • Mong S, Ellingson BM, Nghiemphu PL, Kim HJ, Mirsadraei L, Lai A, Yong W, Zaw TM, Cloughesy TF, Pope WB (2012) Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 33(9):1763-1770
    • (2012) AJNR Am J Neuroradiol , vol.33 , Issue.9 , pp. 1763-1770
    • Mong, S.1    Ellingson, B.M.2    Nghiemphu, P.L.3    Kim, H.J.4    Mirsadraei, L.5    Lai, A.6    Yong, W.7    Zaw, T.M.8    Cloughesy, T.F.9    Pope, W.B.10
  • 23
    • 77954382544 scopus 로고    scopus 로고
    • Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients
    • 20035366 10.1007/s11060-009-0098-8 1:CAS:528:DC%2BC3cXotlCnt78%3D
    • Rieger J, Bahr O, Muller K, Franz K, Steinbach J, Hattingen E (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99:49-56
    • (2010) J Neurooncol , vol.99 , pp. 49-56
    • Rieger, J.1    Bahr, O.2    Muller, K.3    Franz, K.4    Steinbach, J.5    Hattingen, E.6
  • 25
    • 77954730533 scopus 로고    scopus 로고
    • Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
    • 20406897 1:CAS:528:DC%2BC3cXotVWmsbY%3D
    • Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G (2010) Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 12:466-472
    • (2010) Neuro Oncol , vol.12 , pp. 466-472
    • Gerstner, E.R.1    Chen, P.J.2    Wen, P.Y.3    Jain, R.K.4    Batchelor, T.T.5    Sorensen, G.6
  • 26
    • 77949911509 scopus 로고    scopus 로고
    • Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab
    • 19933906 10.1200/JCO.2009.25.0233
    • Gerstner ER, Frosch MP, Batchelor TT (2010) Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 28:e91-e93
    • (2010) J Clin Oncol , vol.28
    • Gerstner, E.R.1    Frosch, M.P.2    Batchelor, T.T.3
  • 27
    • 73349133362 scopus 로고    scopus 로고
    • Diffusion-weighted imaging in head and neck cancers
    • 19792966 10.2217/fon.09.77
    • Chawla S, Kim S, Wang S, Poptani H (2009) Diffusion-weighted imaging in head and neck cancers. Future Oncol 5:959-975
    • (2009) Future Oncol , vol.5 , pp. 959-975
    • Chawla, S.1    Kim, S.2    Wang, S.3    Poptani, H.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.